Clinical trials: RNA
Virus Diseases, RNA Virus Infections
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
This Phase 3 study is intended to assess the clinical lot-to-lot consistency in manufacturing by evaluating and comparing the immunogenicity of three consecutively manufactured lots of the Quadrivalent Virus-Like Particles (VLP)…
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Infections, Respiratory Tract Disease
- Trial name
- NCT03321968
- Testing
- Quadrivalent VLP Influenza Vaccine
- Where
- 10 sites in Canada
- Volunteers
- 1,202 people, healthy volunteers welcome
- Sponsor
- Medicago
Virus Diseases, RNA Virus Infections
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
This Phase 3 study was intended to assess the relative efficacy of the Quadrivalent VLP Influenza Vaccine during the 2018-2019 influenza season compared to a licensed vaccine in elderly adults 65 years of age and older.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT03739112
- Testing
- Quadrivalent VLP Vaccine, Fluarix Quadrivalent® Comparator Vaccine
- Where
- 104 sites in United States, Canada and 3 more
- Volunteers
- 12,794 people, healthy volunteers welcome
- Sponsor
- Medicago
Rabies, Communicable Disease
A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety
This is a Phase 3, blinded, randomized study of SYN023 compared to a China licensed Human Rabies Immunoglobulin (a Rabies immune globulin from human sources, HRIG) for the prevention of rabies as part of post-exposure prophylaxis…
- Conditions
- Rabies, Communicable Disease, Virus Diseases, Rhabdoviridae Infections
- Trial name
- NCT04644484
- Testing
- SYN023, Human Rabies Immune Globulin (HRIG), Rabies Vaccine
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
Novel Oral Anticoagulants, NOACs
Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II
Individual differences in drug efficacy and adverse reactions are common in the clinical application of drugs. Individual differences are caused by many factors, among which genetic factors account for more than 20%.
- Conditions
- Novel Oral Anticoagulants, NOACs, Rivaroxaban, Apixaban
- Trial name
- NCT05764356
- Testing
- Detection of genotype and RNA profile in platelet and white blood cell, Indicators test related to coagulation function, Indicators test related to platelet function
- Where
- 6 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Peking University First Hospital
Human Metapneumovirus and Human Parainfluenza Infection
Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure
This clinical study will assess the safety and immunogenicity of 2 dose levels of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine, in healthy adults (18 to 49 years of age) and 2 dose…
- Trial name
- NCT04144348
- Testing
- mRNA-1653
- Where
- 19 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Asymptomatic Condition, Infection Viral
ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19
Purpose: To determine the number of asymptomatic individuals who have antibodies to SARS-CoV-2, the virus which causes COVID-19
- Conditions
- Asymptomatic Condition, Infection Viral, Coronavirus Infections, Severe Acute Respiratory Syndrome Coronavirus 2
- Trial name
- NCT04367740
- Testing
- To assess for development of IgG antibodies against SARS-CoV2
- Where
- United States
- Volunteers
- 6,313 people
- Sponsor
- University of North Carolina, Chapel Hill
Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome)
EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the most frequent complications of the COVID-19 pandemic.
- Conditions
- Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), Virus Diseases, Coronaviridae Infections
- Trial name
- BEVA (NCT04822818)
- Testing
- BEVA+SOC, SOC
- Where
- France
- Volunteers
- 96 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatitis D, Hepatitis B
Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)
In China, there is no recommendation for Hepatitis D virus (HDV) screening, but the fact is estimated that one-third of the world's population of individuals with chronic Hepatitis B virus (HBV) infection live in China while we…
- Conditions
- Hepatitis D, Hepatitis B, Antibodies; Anti-D, RNA Virus Infections
- Trial name
- NCT05394623
- Testing
- HDV-Ab (IgG), HDV-RNA, RNA genotype
- Volunteers
- 5,000 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Human Immunodeficiency Virus, Alcohol-Related Disorders
Effectiveness & Implementation of a Behavioral Intervention for Adherence and Substance Use in HIV Care in South Africa
The purpose of this study is to test the effectiveness and implementation of a brief, integrated behavioral intervention for HIV medication adherence and substance use in the HIV care setting in South Africa.
- Conditions
- Human Immunodeficiency Virus, Alcohol-Related Disorders, Drug Use
- Trial name
- NCT03529409
- Testing
- Project Khanya
- Where
- 2 sites in United States, South Africa
- Volunteers
- 66 people
- Sponsor
- University of Maryland, College Park
Hepatitis C, Hepatitis
Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination
A community-based "test and treat" intervention integrating point-of-care HCV RNA testing, non-invasive liver disease assessment and linkage to care will lead to a reduction in HCV prevalence among people attending Aboriginal…
- Conditions
- Hepatitis C, Hepatitis, Liver Diseases, Hepatitis, Viral, Human
- Trial name
- SCALE-C (NCT03776760)
- Testing
- Fingerstick GeneXpert HCV RNA quantitative assay, sofosbuvir/velpatesvir, glecaprevir/pibrentasvir
- Where
- 4 sites in Australia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Platelet Aggregation Inhibitors, Aspirin
GM03 - Platelet RNA Signatures of Aspirin
This study will involve healthy volunteers and patients with Type 2 diabetes. Eligible healthy volunteers will be invited to enroll into one of two protocols (A or B) and eligible patients with diabetes will be enrolled into…
- Conditions
- Platelet Aggregation Inhibitors, Aspirin, Ticagrelor, RNA
- Trial name
- NCT05278637
- Testing
- Aspirin, Ticagrelor
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Duke University
RNA Virus Infections
COVID-19 and SARS-CoV-2 Detection in Saliva
This study aims to validate the use of human saliva as a substrate for an assay to detect SARS-CoV-2 and define accuracy, analytical sensitivity and specificity of the TaqPath RT-PCR test.
- Trial name
- NCT04517682
- Testing
- RT-PCR
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Ambry Genetics
Virus Infection, RNA, Effect of Drug
Virucidal Effect of PVP-I on COVID-19 and as Well as Safety of Its Application on Nasopharynx & Oropharynx
The COVID-19 pandemic is the defining global health crisis of our time and the greatest challenge we have faced since World War-II.Corona virus is transmitted via respiratory droplets or aerosol, produced from sneezing or…
- Conditions
- Virus Infection, RNA, Effect of Drug, Efficacy, Self
- Trial name
- COVID-19 (NCT04872686)
- Testing
- 0.6% PVP-I oral and nasal spray to moderately ill COVID-19 positive patient, 0.6% PVP-I Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity, 0.6% PVP-I Oral and nasal spray to healthy volunteer
- Where
- 4 sites in Bangladesh
- Volunteers
- 798 people, healthy volunteers welcome
- Sponsor
- DR. MALA KHAN
COVID-19
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19.
- Trial name
- HERO-HCQ (NCT04334148)
- Testing
- Hydroxychloroquine
- Where
- 34 sites in United States
- Volunteers
- 1,360 people, healthy volunteers welcome
- Sponsor
- Adrian Hernandez
Encephalitis, Encephalitis, Viral
Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine
The primary objective of the study is to evaluate the safety and immunogenicity of non-adjuvanted and adjuvanted monovalent VEE VLP Vaccine in healthy adults (ages 18-50 years) when administered via intramuscular (IM) injection…
- Conditions
- Encephalitis, Encephalitis, Viral, Infectious Encephalitis, Virus Diseases
- Trial name
- VEEV (NCT03776994)
- Testing
- Vaccinations on Day 0, Day 28, and Day 140
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- SRI International
Screening for the Presence of HIV-1, RNA and HBV DNA in Blood Donations
Evaluation of HIV-1, HCV and HBV Blood Screening Tests With Human Blood Donor Specimens
The purpose of this study is to validate the performance characteristics of an assay that tests for HIV-1, HCV and HBV on an automated blood bank instrument for registration submission.
- Trial name
- NCT00552214
- Testing
- Blood test
- Where
- Taiwan
- Volunteers
- 10,290 people, healthy volunteers welcome
- Sponsor
- Novartis
Hematopietic Stem Cell Transplantation, Blood Virome
DNA and RNA Viruses of the Blood Virome of Allogeneic Hematopoietic Stem Cell Transplant Recipients
The Geneva Blood Virome Project is a longitudinal observational study. The main objective is to describe the kinetics of the plasmatic viral load of a selection of at least 21 DNA and RNA viruses of the blood virome in allogeneic…
- Conditions
- Hematopietic Stem Cell Transplantation, Blood Virome, RNA Virus Infections, DNA Virus Infections
- Trial name
- GeBVir (NCT03642977)
- Testing
- Real time PCR and RT-PCR for DNA and RNA viral species
- Where
- Switzerland
- Volunteers
- 112 people
- Sponsor
- University Hospital, Geneva
Covid19, Respiratory Tract Infections
Prevalence and Risk Factors of COVID-19 in the Upper Silesian Agglomeration
Project is designed as a comprehensive population-based epidemiological study in Upper-Silesian Conurbation (Poland) aiming at: 1. analysis of available data on incidence and mortality due to COVID-19 and 2.
- Conditions
- Covid19, Respiratory Tract Infections, Severe Acute Respiratory Syndrome, Corona Virus Infection
- Trial name
- EpiSARS2 (NCT04627623)
- Testing
- IgM and IgG antibodies assay
- Where
- Poland
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Medical University of Silesia
COVID-19
Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19)
Evaluation of the efficacy and safety of NTX in adult patients (≥18 years and <60 years), with SARS-CoV-2 infection with mild symptoms of COVID-19, compared to a placebo control arm.
- Trial name
- NCT04463264
- Testing
- Nitazoxanide
- Where
- Argentina
- Volunteers
- 135 people
- Sponsor
- Laboratorios Roemmers S.A.I.C.F.
Hepatitis C Virus Infection
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection
The primary objective of the study is to evaluate the safety and tolerability of voxilaprevir (formerly GS-9857) alone or with sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) and antiviral activity of voxilaprevir…
- Trial name
- NCT02185794
- Testing
- Voxilaprevir, SOF/VEL
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 101 people
- Sponsor
- Gilead Sciences